State Street Corp Purchases 63,968 Shares of Fractyl Health, Inc. (NASDAQ:GUTS)

State Street Corp grew its position in Fractyl Health, Inc. (NASDAQ:GUTS) by 129.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 113,415 shares of the company’s stock after purchasing an additional 63,968 shares during the period. State Street Corp owned about 0.24% of Fractyl Health worth $287,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GUTS. Rhumbline Advisers acquired a new stake in Fractyl Health during the 2nd quarter worth $32,000. SG Americas Securities LLC bought a new stake in shares of Fractyl Health in the third quarter worth about $33,000. HighTower Advisors LLC acquired a new stake in shares of Fractyl Health during the third quarter worth about $38,000. Beta Wealth Group Inc. bought a new position in shares of Fractyl Health during the 3rd quarter valued at about $44,000. Finally, BNP Paribas Financial Markets grew its position in shares of Fractyl Health by 54.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares during the period.

Fractyl Health Price Performance

NASDAQ GUTS opened at $2.20 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The stock has a market cap of $105.82 million and a price-to-earnings ratio of -0.18. The business has a 50 day simple moving average of $2.28 and a 200 day simple moving average of $2.91. Fractyl Health, Inc. has a 52-week low of $1.74 and a 52-week high of $14.50.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. Analysts anticipate that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Fractyl Health news, insider Jay David Caplan sold 64,197 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares of the company’s stock, valued at $379,253.68. This represents a 29.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $1,213,582.63. This represents a 16.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.